Dose the first patient in the RTX-321 clinical trial
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 11 Jan 2021
- Due
- 31 Dec 2021
- Delivered
- April 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Dose the first patient in the RTX-321 clinical trial in HPV-positive tumors”
What we found
Evidence strength A What the grades mean
The company initiated the RTX-321 Phase 1 clinical trial in April 2021, confirming the first patient was dosed within the 2021 calendar year.
-
A Rubius Therapeutics, Inc. 10-K filed 2022-02-25
“The RTX-321 Phase 1 clinical trial, which we initiated in April 2021, is an open-label, multicenter, multiple-ascending dose, first-in-human study of RTX-321” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Dose
- Deliverable
- First patient dose in RTX-321 trial
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Customer
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Rubius Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C709401-021468 · Corrections policy